A.R.T. Advisors’s Ovid Therapeutics OVID Stock Holding History

A.R.T. Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-35,162	Closed	-$146K	–	706
2019 Q4	$146K	Buy	+35,162	New	+$111K	0.01%	1190

Other funds holding OVID

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

A.R.T. Advisors's OVID Position: Q1 2020 in Review

A.R.T. Advisors sold out of Ovid Therapeutics (OVID) in Q1 2020, closing a stake of 35,162 shares — an estimated $146K sold.

A.R.T. Advisors first reported a position in OVID in Q4 2019 and held it in 1 quarter. The position peaked at $146K in Q4 2019. 57 funds tracked by Wall St. Rank hold OVID as of Q1 2020.

A.R.T. Advisors reported no remaining Ovid Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 35,162 Ovid Therapeutics shares in Q1 2020, an estimated $146K.
A.R.T. Advisors first reported a position in Ovid Therapeutics in Q4 2019 and held it in 1 quarter.
A.R.T. Advisors's Ovid Therapeutics position peaked at $146K in Q4 2019.
57 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.